PURPOSE: This study tested a prediction stemming from the hypothesis that anastrozole users experience heightened vitreo-retinal traction. This hypothesis was based on the knowledge that menopause increases the risk of intraocular tractional events such as posterior vitreous detachments (PVDs). METHODS: Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication. Foveal shape indices were derived for subjects without PVDs. RESULTS: For anastrozole users, the distance to the temporal side of the fovea became less than the distance to the nasal side at a sufficient height above the foveal base. This effect did not exist for control subjects; the between-group difference was appreciable. Results concerning tamoxifen users were inconclusive. CONCLUSIONS: The foveas of women using anastrozole appear to be subjected to more tractional force than are the foveas of women not using any hormonal medication.
PURPOSE: This study tested a prediction stemming from the hypothesis that anastrozole users experience heightened vitreo-retinal traction. This hypothesis was based on the knowledge that menopause increases the risk of intraocular tractional events such as posterior vitreous detachments (PVDs). METHODS: Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication. Foveal shape indices were derived for subjects without PVDs. RESULTS: For anastrozole users, the distance to the temporal side of the fovea became less than the distance to the nasal side at a sufficient height above the foveal base. This effect did not exist for control subjects; the between-group difference was appreciable. Results concerning tamoxifen users were inconclusive. CONCLUSIONS: The foveas of women using anastrozole appear to be subjected to more tractional force than are the foveas of women not using any hormonal medication.
Authors: Alvin Eisner; Maureen D Toomey; Lisa J Incognito; Jean P O'malley; John R Samples Journal: Invest Ophthalmol Vis Sci Date: 2006-12 Impact factor: 4.799
Authors: Mirjam E J van Velthoven; Dirk J Faber; Frank D Verbraak; Ton G van Leeuwen; Marc D de Smet Journal: Prog Retin Eye Res Date: 2006-12-08 Impact factor: 21.198
Authors: Rogério A Costa; Mirian Skaf; Luiz A S Melo; Daniela Calucci; Jose A Cardillo; Jarbas C Castro; David Huang; Maciej Wojtkowski Journal: Prog Retin Eye Res Date: 2006-05-22 Impact factor: 21.198
Authors: Jean Y Chuo; Tracy Y Y Lee; Hussein Hollands; Andrew H Morris; Romina C Reyes; Jonathan D Rossiter; Sarah P Meredith; David A L Maberley Journal: Am J Ophthalmol Date: 2006-09-11 Impact factor: 5.258
Authors: Ann H Partridge; Andrea LaFountain; Erica Mayer; Brooke S Taylor; Eric Winer; Aviva Asnis-Alibozek Journal: J Clin Oncol Date: 2008-01-07 Impact factor: 44.544
Authors: Alvin Eisner; Maureen D Toomey; Julie Falardeau; John R Samples; John T Vetto Journal: Breast Cancer Res Treat Date: 2007-01-27 Impact factor: 4.872
Authors: Dragos Serban; Daniel Ovidiu Costea; Anca Zgura; Mihail Silviu Tudosie; Ana Maria Dascalu; Gabriel Andrei Gangura; Catalin Gabriel Smarandache; Alexandru Dan Sabau; Corneliu Tudor; Mihai Faur; Andreea Cristina Costea; Daniela Stana; Simona Andreea Balasescu; Laura Carina Tribus; Ciprian Tanasescu Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155